Investigating a new treatment to reduce brain damage after traumatic injury.
Official title: Neutrophil extracellular traps and associated pathogenesis in TBI: a novel peptide therapeutic strategy.
Funded at Hackensack University Medical Center · NIH-11049093 · Data updated 2026-11-12
This study is looking at how a type of immune cell can make brain injuries worse after a traumatic brain injury (TBI), and it's testing a new treatment that might help the brain heal better and reduce problems for people recovering from TBI.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | March 6, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $398,475 |
| NIH project number | 5R01NS133233-02 |
| Project ID | NIH-11049093 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced a traumatic brain injury.
✕Less likely to help
Patients with non-traumatic brain injuries or those who do not have significant inflammation may not benefit from this research.
What this research studies
This research focuses on understanding how traumatic brain injury (TBI) leads to inflammation and damage in the brain. It explores the role of neutrophils, a type of immune cell, in forming structures that can worsen injury. The researchers aim to test a new peptide that could inhibit the formation of these structures, potentially improving recovery and reducing complications after TBI. By examining the effects of this peptide on brain healing and function, the study seeks to provide insights into new therapeutic strategies for TBI patients.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that enhances recovery and reduces complications for patients with traumatic brain injury.
How similar studies have gone: While the approach of targeting neutrophil extracellular traps is relatively novel, similar strategies in other inflammatory conditions have shown promise.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Muneer, Mohammed Abdul — Hackensack University Medical Center
- Study coordinator: Muneer, Mohammed Abdul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.